Association between mineral and bone disorder in patients with acute kidney injury following cardiac surgery and adverse outcomes

Table 3 Hazard ratios (HRs) and 95% confidence intervals (CIs) of the 28-day mortality according to the mineral metabolite levels in all 158 patients with AKI

Biomarker	Unadjusted		Model 1		Model 2
Biomarker	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Calcium (mmol/L)	1.42 (0.21, 9.63)	0.710	2.08 (0.30, 14.36)	0.464	2.29 (0.29, 17.90)	0.434
Phosphate (mmol/L)	1.73 (0.72, 4.17)	0.227	2.01 (0.87, 4.68)	0.108	2.62 (1.08, 6.34)	0.035
iPTH (ng/dL)	1.05 (1.01, 1.08)	0.009	1.05 (1.01, 1.08)	0.018	1.04 (1.00, 1.09)	0.046
25D (ng/mL)	0.93 (0.86, 1.01)	0.080	0.93 (0.86, 1.01)	0.091	0.94 (0.86, 1.02)	0.157
BAP (μg/L)	1.03 (0.96, 1.10)	0.395	1.03 (0.96, 1.11)	0.362	1.05 (0.97, 1.13)	0.190
TRACP-5b (U/L)	1.26 (0.83, 1.91)	0.283	1.18 (0.75, 1.83)	0.484	1.37 (0.84, 2.22)	0.206
cFGF23 (RU/μL)	1.26 (1.15, 1.38)	< 0.001	1.37 (1.19, 1.58)	< 0.001	1.37 (1.17, 1.60)	< 0.001

Model 1 is adjusted for age, sex, preoperative eGFR, hypertension, congestive heart failure, and diabetes mellitus. Model 2 is further adjusted for the operation type and APACHE II score. iPTH: intact parathyroid hormone; 25D: 25-hydroxyvitamin D; BAP: bone-specific alkaline phosphatase; TRACP-5b: tartrate-resistant acid phosphatase 5b; cFGF23: C-terminal fibroblast growth factor 23; eGFR: estimated glomerular filtration rate; APACHE: Acute Physiology and Chronic Health Evaluation

ISSN: 1471-2369